Literature DB >> 6332693

Serum IgG levels and complement activity in hypogammaglobulinaemic patients under substitution therapy.

A Plebani, L D Notarangelo, M Duse, A Avanzini, M Massa, A G Ugazio.   

Abstract

Haemolytic activity of the classical and alternative pathways of complement as well as serum levels of C1q, Factor B, Factor H, C3, C4, C3d,g and IgG were determined in 15 hypogammaglobulinaemic patients on immunoglobulin replacement therapy. Alternative pathway activity (AP) and C1q were defective in the presence of low IgG levels and normalized on achievement of normal IgG levels; for both variables the correlation with serum IgG was highly significant. Classical pathway activity (CP), C3, C4 and Factor H serum levels were normal independently of IgG levels; Factor B and C3d, g serum levels were elevated in hypogammaglobulinaemic patients regardless of IgG levels. The present report supports the hypothesis that IgG serum levels influence complement function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332693      PMCID: PMC1576950     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement.

Authors:  B Nelson; S Ruddy
Journal:  J Immunol       Date:  1979-05       Impact factor: 5.422

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Complement-immunoglobulin relation: deficiency of C'1q associated with impaired immunoglobulin G synthesis.

Authors:  P F Kohler; H J Müller-Eberhard
Journal:  Science       Date:  1969-01-31       Impact factor: 47.728

4.  Subcutaneous infusion of gamma globulins in the management of agammaglobulinemic patients.

Authors:  A G Ugazio; M Duse; A Plebani; L D Notarangelo; G R Burgio
Journal:  Birth Defects Orig Artic Ser       Date:  1983

5.  Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation.

Authors:  R B Polhill; S L Newman; K M Pruitt; R B Johnston
Journal:  J Immunol       Date:  1978-07       Impact factor: 5.422

6.  Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus.

Authors:  P F Kohler; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1972-04       Impact factor: 14.808

7.  Activity of the alternative complement pathway after splenectomy: comparison to activity in sickle cell disease and hypogammaglobulinemia.

Authors:  J M Corry; R B Polhill; S R Edmonds; R B Johnston
Journal:  J Pediatr       Date:  1979-12       Impact factor: 4.406

8.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

9.  The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum.

Authors:  A W Hill; A L Shears; K G Hibbitt
Journal:  Immunology       Date:  1978-01       Impact factor: 7.397

10.  Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins.

Authors:  R D Schreiber; D C Morrison; E R Podack; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1979-04-01       Impact factor: 14.307

View more
  2 in total

1.  Analysis of immunoglobulin, complements and CRP levels in serum of captive northern pig-tailed macaques (Macaca leonina).

Authors:  Xiao-Liang Zhang; Wei Pang; De-Yao Deng; Long-Bao Lv; Yue Feng; Yong-Tang Zheng
Journal:  Dongwuxue Yanjiu       Date:  2014-05

2.  Primary immunodeficiency in infection-prone children in southern Sweden: occurrence, clinical characteristics and immunological findings.

Authors:  Nicholas Brodszki; Göran Jönsson; Lillemor Skattum; Lennart Truedsson
Journal:  BMC Immunol       Date:  2014-08-14       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.